Related Experiment Videos
Danger signals: Chemotherapy enhancers?
Thaiz Rivera Vargas1,2, Lionel Apetoh1,2,3
1Centre de Recherche, INSERM U1231, Facultés de Médecine et de Pharmacie, Dijon, France.
Immunological Reviews
|October 14, 2017
Summary
Chemotherapy-released danger signals, like HMGB1 and DNA, activate anticancer immune responses. Understanding these signals is key for developing effective chemoimmunotherapies against cancer.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Endogenous danger signals are released from stressed cells, initiating immune responses.
- Dying tumor cells treated with chemotherapy release danger signals, such as High-Mobility Group Box 1 (HMGB1) protein and DNA.
- These released molecules can stimulate anticancer immunity.
Purpose of the Study:
- To discuss the molecular characteristics of endogenous danger signals released from chemotherapy-treated tumor cells.
- To focus on the clinical relevance of using these danger signals in chemoimmunotherapeutic strategies against cancer.
Main Methods:
- Review of scientific literature on danger signals, chemotherapy, and cancer immunity.
- Analysis of molecular mechanisms underlying danger signal release and recognition.
- Evaluation of clinical applications of danger signals in cancer therapy.
Main Results:
- Chemotherapy induces the release of danger signals like HMGB1 and DNA from tumor cells.
- These danger signals activate anticancer immune responses.
- Novel cytosolic DNA sensors enhance understanding of DNA's immunostimulatory role.
Conclusions:
- Endogenous danger signals released by chemotherapy-treated tumors are crucial for initiating anticancer immunity.
- Exploiting these danger signals holds significant promise for developing novel chemoimmunotherapeutic strategies.
- Further research into danger signal characteristics and clinical applications is warranted.